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Abstract
Background: Androgen deprivation therapy (ADT) is the mainstay therapy for men with prostate cancer. However,
there are musculoskeletal side effects from ADT that increase the risk for osteoporosis and fracture, and can
compromise the quality of life of these individuals. The objectives of this study are to determine the efficacy of a
home-based walking exercise program in promoting bone health, physical function and quality of life in men with
prostate cancer receiving ADT.
Methods/Design: A 12-month prospective, single-blinded, randomized controlled trial will be conducted to
compare the Exercise Group with the Control Group. Sixty men with prostate cancer who will be starting ADT will
be recruited and randomly assigned to one of the two groups: the Exercise Group will receive instructions in
setting up an individualized 12-month home-based walking exercise program, while the Control Group will receive
standard medical advice from the attending physician. A number of outcome measures will be used to assess
bone health, physical function, and health-related quality of life. At baseline and 12 months, bone health will be
assessed using dual-energy X-ray absorptiometry. At baseline and every 3 months up to 12 months, physical
function will be evaluated using the Functional Assessment of Chronic Illness Therapy - Fatigue Scale, Activities-
specific Balance Confidence Scale, Short Physical Performance Battery, and Six-Minute Walk Test; and health-related
quality of life will be assessed using the Functional Assessment of Cancer Therapy Prostate Module and the
Medical Outcomes Study 12-item Short Form Health Survey Version 2. A mixed multiple analysis of variance will be
used to analyze the data.
Discussion: Musculoskeletal health management remains a challenge in men with prostate cancer receiving ADT.
This study addresses this issue by designing a simple and accessible home-based walking exercise program that
will potentially have significant impact on reducing the risk of fracture, promoting physical function, and ultimately
improving the health-related quality of life in men with prostate cancer receiving ADT.
Trial registration: ClinicalTrials.gov: NCT00834392.
Keywords: Prostate cancer, Androgen deprivation therapy, Walking, Home-based exercise, Bone health, Physical
function, Quality of life
Background
Prostate cancer is the most commonly diagnosed cancer
among men in North America, excluding non-mela-
noma skin cancer. There are currently 25,500 men in
Canada [1] and over 2.3 million men in the United
States who have prostate cancer [2]. Despite apparently
localized and hence curable disease at presentation,
more than one-third of men with prostate cancer will
develop recurrent disease. Androgen deprivation therapy
(ADT), accomplished by bilateral orchiectomy or the
use of a luteinizing hormone-releasing hormone
(LHRH) agonist, is the mainstay therapy for recurrent
and/or metastatic prostate cancer. The duration of
response to ADT using an LHRH agonist ranges from
12 to 18 months, with 20% of patients having a com-
plete prostate specific antigen (PSA) response at 5 years
[3]. However, there are a number of side effects of ADT
that negatively impact the health-related quality of life
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any medium, provided the original work is properly cited.in these men. The side effects of such treatment include
osteoporosis, [4,5] increased fracture risk, [6-8] poorer
quality of life with decline in physical function, [9,10]
fatigue, decline in muscle mass, increased fat mass,
weight gain, [11,12] reduced psychosocial and cognitive
functions [13,14]. Osteoporosis and physical function
decline are of particular concern as these are factors
that are closely related to risks of falls and fractures in
older men [15-18].
Exercise is an easily accessible lifestyle intervention
that may have significant positive impact on the quality
of life in men with prostate cancer. A number of studies
have already shown that exercise improves the quality of
life and even survivorship in women with breast cancer
[19,20]. However, there are few studies investigating the
effects of exercise on bone health and physical function
in men with prostate cancer. Walking has been shown
to have beneficial effects on bone metabolism in post-
menopausal women [21]. We speculate that walking
may have a similar effect on bone metabolism in men
with prostate cancer receiving ADT. In addition, a study
showed that short-term supervised, rigorous resistance
exercise could reduce fatigue and improve muscular fit-
ness, and improve some aspects of quality of life in men
with prostate cancer receiving ADT [22]. Therefore, it is
imperative to explore other forms of exercise that can
achieve similar results as resistance exercise, but are
more accessible and can be readily incorporated into the
long-term lifestyle of men with prostate cancer. The
purpose of this study is to determine the efficacy of a
home-based walking exercise program in promoting
bone health, physical function and quality of life in men
with prostate cancer receiving ADT.
Methods/Design
A 12-month prospective, single-blinded, randomized
controlled pilot study will be conducted to compare an
Exercise Group with a Control Group. The study will be
conducted in the Department of Physical Therapy in the
Faculty of Medicine at the University of Manitoba.
Patient recruitment will be conducted through Cancer
Care Manitoba, with baseline and follow-up sessions at
the Department of Physical Therapy at University of
Manitoba. The University of Manitoba Research Ethics
Board has approved the study protocol (Ethics Reference
# H2008:035), which is also in compliance with the Hel-
sinki Declaration.
Participants
Inclusion criteria
Patients will be included in the study if they are men
aged 50 years or older, diagnosed with adenocarcinoma
prostate cancer, and who will initiate and receive con-
tinuous ADT (LHRH agonist alone or in combination
with another anti-androgen) for at least 12 months after
recruitment. Patients will be required to provide written
informed consent to participate in the study.
Exclusion criteria
Patients will be excluded from the study if they have
severe cardiac disease (New York Heart Association
class III or greater), angina, pre-existing osteoporosis
with T-score at or below -2.5, stable bone lesion, uncon-
trolled hypertension (blood pressure > 160/95 mm Hg),
moderate to severe aortic stenosis, acute illness or fever,
uncontrolled atrial or ventricular dysrhythmias, uncon-
trolled sinus tachycardia (> 120 beats per minute),
third-degree atrio-ventricular heart block, active pericar-
ditis or myocarditis, recent pulmonary embolism, deep
vein thrombosis, uncontrolled diabetes, uncontrolled
pain, cognitive impairment, history of falls due to bal-
ance impairment or loss of consciousness, severe neuro-
musculoskeletal conditions that limit their ability to
perform walking exercise (including ataxia, peripheral or
sensory neuropathy, unstable bone lesion, severe arthri-
tis, pathological lower limb fractures within 6 months,
lower limb amputation).
Recruitment
A total of 60 patients will be consecutively recruited
during the initial 3-months of the study from office
visits at Cancer Care Manitoba. The attending physi-
cian will screen the patients for inclusion criteria (men
aged 50 or older), diagnosed with prostate adenocarci-
noma, will initiate and receive continuous ADT
(LHRH alone or in combination with another anti-
androgen for at least 12 months). If the patients meet
the preliminary inclusion criteria, the physician will
refer them to a clinical research nurse who will con-
firm that all inclusion and exclusion criteria are met,
explain the study protocol, provide information sheet,
and obtain written informed consent from any patients
who would like to participate in the study. The clinical
research nurse will provide a graduate research assis-
tant (GRA1) with the signed consent forms and con-
tact information of the patients who have agreed to
participate in the study.
Assessment sessions
Each participant will attend a total of five assessment
sessions: one baseline, and four follow-up sessions at 3,
6, 9, and 12 months after ADT initiation. The Exercise
Group will complete telephone survey between follow-
up sessions.
Baseline assessment session
GRA1 will contact the participants to schedule a base-
line assessment. GRA1 will collect the socio-demo-
graphic and clinical characteristics, followed by primary
outcome (HRQOL and physical function) and secondary
Lee et al. BMC Cancer 2012, 12:103
http://www.biomedcentral.com/1471-2407/12/103
Page 2 of 6outcome variables (physical fitness, psychosocial-cogni-
tive functions, and physical activity).
GRA2 (another graduate research assistant) will pro-
vide each participant with a pedometer to monitor his
ambulatory activities. The participants will be instructed
to wear the pedometer during waking hours, except
while bathing or swimming. The pedometer will be
worn on a waistband, at or slightly anterior to the mid-
axillary line. The exact location will be determined by a
50-step trial walk, and the placement that yields the
least percentage error in step counts will be used for the
individual’s daily application. Pedometer daily logs, self-
addressed envelopes, and extra batteries will be provided
to all participants. At the end of each day, participants
will record the date, total daily time wearing the ped-
ometer, and the number of daily steps taken, and then
reset the pedometer to zero. Every four weeks, GRA2,
will call the participants to remind them to return their
pedometer daily logs by mail in the self-addressed
envelopes.
Randomization of group assignment
GRA1 will be blinded to the group assignments of the
participants. Therefore, after the baseline assessment
and pedometer instruction, GRA2 will be responsible
for the randomized group assignment. GRA2 will assign
the participant the first available number from a ran-
domly generated list consisting of “1” and “2”.N u m b e r
“1” is designated as the Exercise Group that will receive
instructions in setting up an individualized 12-month
home-based walking exercise program in addition to
their daily activities. Number “2” is designated as the
Control Group that will be advised to perform daily
activities as usual and follow the standard medical
advice from their attending physician.
Exercise group protocol
GRA2 will assess the baseline health and fitness of the
participants of the exercise group by using an exercise
screening form that includes the revised Physical Activ-
ity Readiness Questionnaire (PAR-Q), [23] and other
screen questions for exercise contraindications and pre-
cautions. If any exercise contraindication is identified (e.
g. shortness of breath, severe headache, sudden onset of
numbness or weakness), the participant will be excluded
from the study and referred to their family physician for
investigation. If any exercise precautions is identified (e.
g. fever, severe cachexia, extreme fatigue, sickness or
bone pain), high-intensity or high-impact exercise will
be initially avoided. If severe nausea or calf pain is pre-
sent, the participants will be advised to consult their
family physician for further investigation and clearance
prior to beginning the exercise program.
The Exercise Group will follow a walking exercise
p r o g r a mt h a tc o m p r i s e sap r o gressive structured exer-
cise protocol and progressive target daily step counts.
The structured exercise protocol will initially begin
with a 10-minute walking session, 3 sessions per week.
The Exercise Group participants will be instructed to
perform a 5-minute warm-up period by walking slowly
prior to the 10-minute walking session. There will also
be a 5-minute cool-down period by walking slowly, fol-
lowed by a stretching routine after the 10-minute
walking session. The stretching instruction sheet will
be provided to the participants. GRA2 will also educate
and demonstrate to the participants how the stretches
a r et ob ed o n e .D u r i n gt h ew a r m - u p / c o o l - d o w np e r i -
ods, the participants will maintain an exertion level
between 7.5 and 8 on the Borg Scale of Ratings of Per-
ceived Exertion (RPE) [24] (i.e., extremely light level of
exertion). During the 10-minute walking session, the
participants will gradually increase the walking speeds
until they attain and maintain an RPE level between 9
and 13 (i.e., very light to light exertion) according to
their baseline physical activity level (sedentary, moder-
ately active, or active) as reported on their self-
reported physical activity questionnaire. Sedentary
individuals will walk at RPE level 9 (very light exer-
tion), moderately active individuals will walk at RPE
level 11 (light exertion), and active individuals will
exercise at RPE level 13 (somewhat hard exertion).
Each participant’s exercise level will be progressed
every two week, first in frequency (1-day increment),
then duration (5-minute increment), and lastly RPE
level. Based on the set progression protocol, the Exer-
cise Group participants will be performing five walking
exercise sessions per week, 30 minutes walking per
session, and will attain RPE level 15 (heavy exertion)
during the walking session by around 18 to 20 weeks.
This level of exercise protocol will be maintained for
the rest of the study period. The participants are
instructed to record the date, start time, exercise dura-
tion and maximum RPE attained during each session
in an exercise daily log. The participants will also be
encouraged to walk at their chosen pace at times out-
side their structured exercise protocol so as to achieve
their assigned target daily step counts. The initial tar-
get will be set at 5,000 steps for sedentary individuals,
6000 steps for moderately active individuals, and 7,000
steps for active individuals. The target daily step
counts will be progressed every two weeks (1000-steps
increment) up to a maximum daily target of 10,000
steps. The participants will be counseled on the warn-
ing symptoms of impending cardiovascular events
including chest pain or discomfort, shortness of breath,
dizziness, severe headache, sudden onset of numbness
or weakness, or calf pain suggestive of deep vein
thrombosis. They will be strongly advised to discon-
tinue the exercise program and report these symptoms
to their attending physician and GRA2 immediately.
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vided to the Exercise Group participants.
Between follow-up sessions
For the first 20 weeks, GRA2 will call the Exercise
Group participants every two weeks to monitor their
safety, adherence, and progress using a short, structured
phone survey. The results of the phone survey will be
used to guide the adjustments/progression of the struc-
tured exercise and step counts protocols. After 20
weeks, GRA2 will conduct the phone survey every four
weeks. In addition, the participants will return their
exercise daily logs every four weeks.
Follow-up sessions
GRA1 will schedule follow-up sessions for all partici-
pants at 3, 6, 9, and 12 months after ADT initiation. Pri-
mary outcome (HRQOL and physical function) and
secondary outcome variables (physical fitness, psychoso-
cial-cognitive functions, and physical activity) will be re-
assessed during the follow-up sessions.
Data collection
At baseline session, GRA1 will collect independent
variables of socio-demographic, clinical, and behavioral
factors using a structured assessment questionnaire.
Socio-demographic factors will include (1) age, (2)
marital status, (3) ethnicity, (4) living arrangement, (5)
education, (6) work status, (7) alcohol consumption
history, and (8) smoking history. Clinical factors will
include (9) current cancer stage, (10) time since diag-
nosis, (11) treatment intent (i.e., curative vs. palliative).
Other baseline data including testosterone level, Glea-
son score, and comorbidities will be obtained from the
medical records.
At baseline and 12-months after ADT initiation,
GRA1 will obtain bone mineral density (for bone health
as part of the primary outcomes) of the lumbar spine,
hip and whole body and body composition (for physical
fitness as part of the secondary outcomes) of the whole
body from the dual-energy x-ray absorptiometry (DXA),
a and PSA level from the medical records.
At baseline and all follow-up sessions (3, 6, 9, and 12
months), the rest of the primary (HRQOL and physical
function) and secondary outcome variables (physical fit-
ness, psychosocial-cognitive functions, and physical
activity) will be assessed. HRQOL will be assessed using
(1) the Functional Assessment of Cancer Therapy Pros-
tate Module (FACT-P) [25] as a disease-specific instru-
ment, and (2) the Medical Outcomes Study 36-item
Short Form Health Survey Version 2 (SF-36v2) [26] as
generic instrument that is chosen for its depth of cover-
age, breadth of domains, and widespread use in medical
outcomes assessment. Physical function will be assessed
using (3) the Functional Assessment of Chronic Illness
Therapy (FACIT) - Fatigue scale [27] that evaluates self-
reported fatigue level; (4) the Activities-specific Balance
Confidence (ABC) Scale [28] that evaluates the self-
reported confidence in activities of daily living; (5) the
Short Physical Performance Battery (SPPB) [29,30] that
objectively assesses lower extremity function including
standing balance, gait speed, and ability to rise from a
chair; and (6) the 6-Minute Walk Test (6MWT) [31]
that evaluates walking endurance. Physical fitness will be
assessed using (7) the body mass index based on the
participants’ height and weight measurement obtained
by a standard medical weight scale. Psychosocial-cogni-
tive functions will be assessed using (8) the Multidimen-
sional Health Locus of Control (MHLC) Form C [32]
for individuals’ beliefs regarding where the control over
their health lies; (9) the Center for Epidemiological Stu-
dies Depression (CES-D) [33] for depression; and (10)
the Prospective Retrospective Memory Questionnaire
(PRMQ) for short and long-term memory. Physical
activity will be assessed using (11) the Rapid Assessment
of Physical Activity [34]. Physical activity is also assessed
based on the completed pedometer daily logs returned
by all participants every four weeks.
Exercise group
Exercise adherence of the Exercise Group participants
will be monitored by the exercise daily logs returned
every four weeks, and phone surveys conducted by
GRA2 every two weeks for the first 20 weeks and every
four weeks for the rest of the study period. The phone
surveys also monitor exercise safety and progress.
Statistical analysis
Primary outcome variables
A mixed multiple analysis of variance (MANOVA)
(Group X Time) will be conducted to determine if there
is a significant interaction between the between- group
(Group) and within-group (Time) comparisons for:
Bone health (bone mineral density) at baseline and 12-
month follow-up session;
HRQOL (FACT-P and SF-36), and physical function
(FACT-Fatigue, ABC, SPPB, and 6MWT) at baseline, 3,
6, 9, and 12-month follow-up sessions.
Secondary outcome variables
A mixed MANOVA (Group X Time) will be conducted
to determine if there is a significant interaction between
the between-group (Group) and within-group (Time)
comparisons for:
- Physical fitness (body composition) reflected in lean
body mass at baseline and 12-month follow-up session;
Physical fitness (body mass index), psychosocial-cogni-
tive functions (MHLC Form C, CES-D, and PRMQ), and
physical activity (RAPA, daily step counts based on the
pedometer daily logs) at baseline, 3, 6, 9, and 12-month
follow-up sessions.
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product-moment correlation will be performed to deter-
mine if socio-demographic (age, marital status, living
arrangement, education, and work status) and clinical
factors (current cancer stage, time since diagnosis, treat-
ment intent, testosterone level, Gleason score, comor-
bidity index, and PSA level) are associated with exercise
adherence (average percentage of adherence to the tar-
get exercise frequency, duration and intensity based on
t h ee x e r c i s ed a i l yl o g s )a n dexercise safety (occurrence
rate of safety issues from the phone survey).
Discussion
Bone health management remains a challenge in men
with prostate cancer receiving ADT. The primary objec-
tive of the study is to determine the feasibility and effi-
cacy of a simple and accessible home-based walking
exercise program in promoting bone health, health-
related quality of life, and physical function in men with
prostate cancer receiving ADT as compared to a control
group. This study is significant because a successful
home-based exercise program for men with prostate
cancer would be cost-effective, and has a potentially sig-
nificant impact on a number of comorbidities that are
related to ADT. This multidisciplinary study lays the
foundation for the development of a prevention and
wellness program within a multidisciplinary, compre-
hensive cancer care program for men with prostate
cancer.
Endnote
aDXA is part of a standard patient care for men with
prostate cancer on ADT. The test is performed to moni-
tor bone mineral density of total body, at lumbar spine
and femur sites. Total body composition is based on
additional analysis of the total body DXA results.
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